Summary

Eligibility
for males ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
study ends around
Principal Investigator
by Amar U. Kishan, MD (ucla)
Headshot of Amar U. Kishan
Amar U. Kishan

Description

Summary

This phase II trial investigates the effect of extremely hypofractionated intensity modulated stereotactic body radiotherapy in treating patients with prostate cancer that has rising prostate specific antigen (PSA) after radical prostatectomy. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.

Official Title

Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for Adjuvant or Salvage Treatment for Rising PSA After Radical Prostatectomy (EXCALIBUR)

Details

Keywords

Prostate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Prostatic Neoplasms, Hormones, Hormone Therapy, Stereotactic Body Radiation Therapy

Eligibility

Location

  • UCLA / Jonsson Comprehensive Cancer Center accepting new patients
    Los Angeles California 90095 United States

Lead Scientist at University of California Health

  • Amar U. Kishan, MD (ucla)
    Department Vice Chair, Radiation Oncology, Medicine. Authored (or co-authored) 306 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Jonsson Comprehensive Cancer Center
ID
NCT04915508
Phase
Phase 2 Prostate Cancer Research Study
Study Type
Interventional
Participants
Expecting 102 study participants
Last Updated